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Training in flexible, intensive insulin management to
enable dietary freedom in people with type 1 diabetes:
dose adjustment for normal eating (DAFNE) randomised
controlled trial
DAFNE Study Group
Abstract
Objectives To evaluate whether a course teaching
flexible intensive insulin treatment combining dietary
freedom and insulin adjustment can improve both
glycaemic control and quality of life in type 1 diabetes.
Design Randomised design with participants either
attending training immediately (immediate DAFNE)
or acting as waiting list controls and attending
“delayed DAFNE” training 6 months later.
Setting Secondary care diabetes clinics in three
English health districts.
Participants 169 adults with type 1 diabetes and
moderate or poor glycaemic control.
Main outcome measures Glycated haemoglobin
(HbA1c), severe hypoglycaemia, impact of diabetes on
quality of life (ADDQoL).
Results At 6 months, HbA1c was significantly better in
immediate DAFNE patients (mean 8.4%) than in
delayed DAFNE patients (9.4%) (t=6.1, P < 0.0001).
The impact of diabetes on dietary freedom was
significantly improved in immediate DAFNE patients
compared with delayed DAFNE patients (t= − 5.4,
P < 0.0001), as was the impact of diabetes on overall
quality of life (t=2.9, P < 0.01). General wellbeing and
treatment satisfaction were also significantly
improved, but severe hypoglycaemia, weight, and
lipids remained unchanged. Improvements in
“present quality of life” did not reach significance at 6
months but were significant by 1 year.
Conclusion Skills training promoting dietary
freedom improved quality of life and glycaemic
control in people with type 1 diabetes without
worsening severe hypoglycaemia or cardiovascular
risk. This approach has the potential to enable more
people to adopt intensive insulin treatment and is
worthy of further investigation.
Introduction
Self management is essential to successful treatment of
type 1 diabetes, yet few patients alter their insulin from
day to day or achieve the degree of glycaemic control
known to be ideal.1 The diabetes control and complica›
tions trial showed the long term benefits of strict
glycaemic control.2 However, the intensive approach
used in the trial involved frequent outpatient visits with
close supervision of insulin dose adjustment and has
not been incorporated into general diabetes practice.
The increased risk of severe hypoglycaemia in the
diabetes control and complications trial may be
unacceptable, and the staffing ratio of around three
patients to each healthcare professional is beyond the
scope of most healthcare systems.
Other reasons why intensified treatment has not
been widely adopted may exist. Clinicians usually pro›
pose treatment goals formulated from the medical
perspective, focusing on biomedical outcomes,
whereas patients are more concerned about the imme›
diate demands of treatment and how to integrate these
into daily life.3 Diabetes and its treatment have a nega›
tive impact on quality of life, particularly in terms of
dietary restrictions imposed by traditional treatment
regimens.4 5 It has been argued elsewhere that an
approach in which intensive insulin management is
used to increase dietary freedom is likely to improve
quality of life,6 as well as biomedical outcomes, and may
result in its wider adoption.
For over 20 years, a team from Dusseldorf has used
a five day structured inpatient training programme in
intensive insulin treatment, producing sustained
improvements in glycaemic control without increasing
severe hypoglycaemia.7 Participants are taught to
match insulin doses to their food choices, while
keeping their blood glucose close to normal. In
contrast to the diabetes control and complications trial,
patients maintain this behaviour with minimal support
from healthcare professionals.
We tested this approach in a UK multicentre
randomised controlled study, the dose adjustment for
normal eating (DAFNE) trial, in which we measured
biomedical and psychological outcomes, including
quality of life.
Methods
Participants and protocol
We recruited patients attending hospital diabetes clin›
ics in Sheffield, Northumbria, and London. We consid›
ered patients to be eligible if they were aged over 18
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years with clinical features of type 1 diabetes, moderate
or poor glycaemic control (HbA1c 7.5›12%), and dura›
tion of diabetes of more than two years without
advanced complications. Exclusion criteria included
inability to understand written and spoken English,
severe psychiatric illness, pregnancy, and complete
unawareness of hypoglycaemia.
We recruited participants by a single invitation
letter sent to all patients identified from clinic registers
as fulfilling the eligibility criteria. Respondents were
invited to an evening meeting to discuss the DAFNE
approach.
After obtaining written informed consent, we
randomised volunteers into a waiting list controlled
trial, either to attend a five day training course
delivered in groups of six to eight participants in each
centre (immediate DAFNE) or to continue to receive
usual care for six months as controls and then attend a
course (delayed DAFNE). We randomised participants
by using a computer generated random number list,
prepared for each of the three centres. Before recruit›
ment, one researcher in each centre transferred the
assignments on to slips of paper and placed them
within sealed, opaque envelopes. When provided with
lists of names recorded in the order in which
participants gave consent, the researchers assigned
participants by opening the envelopes in order.
All participants received an explanation of DAFNE
principles at enrolment, before courses were held.
After participating in a course, patients returned to
their usual clinic and, although free to contact the edu›
cators for advice, were not offered specific follow up.
The local ethics committees of the three hospitals
approved the study.
The skills course
An underlying assumption was that type 1 diabetes is
an insulin deficiency disorder, best managed by insulin
replacement as needed and not by dietary manipu›
lation to match prescribed insulin. The course
provided the skills to enable patients to replace insulin
by matching it to desired carbohydrate intake on a
meal by meal basis. This was taught as a five day
(Monday to Friday) outpatient programme using prin›
ciples of adult education with explicit learning
objectives in a group setting. The educators aimed to
build confidence and appropriate independence, with
patient autonomy as a goal. Participants were intended
to acquire the skills and confidence to adjust insulin to
suit their lifestyle rather than being told to adapt the
timing and content of meals to more fixed doses of
insulin. The educational resources and curriculum
were translated by the Dusseldorf team in collabora›
tion with the UK educators.
Two or three educators (diabetes specialist nurses
and dietitians) taught the course in each centre.
Besides preparing the curriculum and teaching
materials, the educators attended a training course run
by members of the departments of education of the
universities of Newcastle and Durham. Appraisers
trained in educational inspection visited one course in
each centre to ensure that the course was taught to
high standards and was similar between centres.
Courses were also peer reviewed by educators from
other centres. A nurse educator from Dusseldorf
observed and reported formally on at least one day of
a course in each centre.
Primary outcomes
A central laboratory measured glycated haemoglobin
(HbA1c) by using a high performance liquid chroma›
tography, diabetes control and complications trial
aligned method (Eurogenetic Tosoh 2.2). The top of
the reference range for people without diabetes was
6.1%. Patients recorded severe hypoglycaemic episodes
(that is, episodes causing coma or requiring the assist›
ance of another person) in blood glucose monitoring
diaries.
We used the audit of diabetes›dependent quality of
life (ADDQoL) questionnaire to measure the impact of
diabetes on quality of life. This tool produces a diabetes
impact rating weighted by importance for 18
potentially applicable domains of life, including dietary
freedom.5 The average weighted impact is a composite
score of all applicable domains indicating individual›
ised impact of diabetes on quality of life. Scores for
single domains and average weighted impact can
range from − 9 (maximum negative impact of
diabetes) to +9 (maximum positive impact of diabetes).
The questionnaire also includes a single item measur›
ing “present quality of life,” with scores ranging from
− 3 (extremely bad) to +3 (excellent).
Secondary outcomes
We measured satisfaction with treatment by using the
diabetes treatment satisfaction questionnaire (DTSQ),8
which includes eight items, six of which form a scale
(scored 0›36) in which higher scores indicate greater
treatment satisfaction. Two individual items (scored
0›6) measure perceived frequency of hyperglycaemia
and hypoglycaemia. Higher scores indicate greater
perceived frequency. Psychological wellbeing was
measured with the 12›item well›being questionnaire
(W›BQ12),9 which is scored from 0 to 36, with higher
scores indicating better general wellbeing.
Weight was measured by using electronic scales.
Blood pressure was measured by using a standard
mercury sphygmomanometer, with phase 5 denoting
diastolic pressure. Each of the three local laboratories
used standard methods to measure serum cholesterol,
triglycerides, and high density lipoprotein cholesterol.
Patients recorded in their diaries the number of insulin
injections, total insulin dose, and blood glucose
monitoring.
Analysis
The study was powered on the expectation that 120
patients would be evaluated. This had 80% power to
detect a difference of 1% in HbA1c (based on 2% stand›
ard deviation in both groups; P < 0.05 two tailed). Data
at each time point are expressed as mean (SD). We
compared outcomes at six months by using unpaired t
tests and 95% confidence intervals. We checked data
for normality and transformed skewed variables by
using square root, log, and inverse transformations
where appropriate.10 We used a ÷2 test to compare the
proportions of patients experiencing severe hypogly›
caemia in the two groups at six months and at 12
months. To examine longer term effects of training in
the immediate DAFNE group, we also performed
paired t tests with baseline and 12 month data.
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Results
Recruitment
We sent letters of invitation to 1016 addresses, and 423
(42%) forms were returned. Of the 404 patients still
living at the address, 299 (74%) expressed interest in
the study and 105 declined. Of these 299, 138 attended
an evening meeting, of whom 128 (93%) decided to
participate; another 41 were recruited without
attending a meeting. Recruitment stopped when the all
the places on the courses had been booked.
Participant flow and follow up
One hundred and sixty nine patients were randomised,
but 27 did not attend a course for reasons such as work
commitments (fig 1). These patients did not attend fur›
ther, so an intention to treat analysis was not possible.
Only one person dropped out during a course. One
participant in immediate DAFNE was found “dead in
bed” six months after the course. One person did not
attend the six month assessment, and four people did
not attend the 12 month assessment. Thus we analysed
data from 140 participants at six months and data from
68 immediate DAFNE participants at 12 months (fig 1).
One hundred and thirty six (97%) participants
completed questionnaires at baseline and six months;
62 (91% of 68) participants in the immediate DAFNE
group completed questionnaires at baseline and 12
months.
Participants’ mean age was 40 (SD 9) years, and the
mean duration of diabetes was 16.6 (9.6) years. Seventy
six (56%) participants were women. Fifty two (37%)
participants had retinopathy, 19 (13%) had peripheral
neuropathy, and two had nephropathy. No significant
differences existed between the two groups at baseline
in terms of participants’ characteristics or primary or
secondary endpoints or between the immediate
DAFNE group at baseline and the delayed DAFNE
group at six months (that is, immediately pre›course).
Primary endpoints
Table 1 shows the primary outcome data. At six
months, HbA1c was significantly improved in the
immediate DAFNE group compared with the delayed
DAFNE group (clinically important mean improve›
ment of 1%). We found no significant difference in the
proportion of the immediate DAFNE group who
experienced severe hypoglycaemia compared with the
delayed DAFNE group. For the quality of life measures,
the immediate DAFNE group showed significant
improvements in the negative impact of diabetes on
dietary freedom in particular (“freedom to eat as I wish
score”) and the impact on quality of life in general
(average weighted impact score) compared with the
delayed DAFNE group.
The qualitative data collected illustrate the personal
importance of these improvements to participants.
299 volunteers (L=109; S=81; N=109)
Immediate DAFNE (n=84)
11 did not start course
3 ineligible
1 participant dropped out
on first day of course
1 participant in hospital
during follow up 1
12 did not start course
1 ineligible
Delayed DAFNE (n=85)
Baseline assessment:
2 weeks pre-course (n=69)
Completed DAFNE
training courses (n=69)
Baseline assessment:
6 months pre-course (n=72)
169 randomised (L=57; S=57; N=55)
Completed DAFNE
training courses (n=72)
Follow up 1:
6 months post-course (n=68)
Follow up 1:
2 weeks pre-course (n=72)
Follow up 2:
12 months post-course (n=68)
Feb - May
2000
Sep - Dec
2000
Feb - May
2001
Follow up 2:
6 months post-course (n=68)
1 participant died
(38 days after follow up 1)
Participant who did not
complete follow up 1
available for follow up 2
1 participant had stroke and
had to withdraw from trial
3 did not attend follow up 2
141 completed course (L=46; S=48; N=47)
Fig 1 Flow of participants through study (L=London; S=Sheffield; N=Northumbria)
Table 1 Primary outcomes: differences between immediate DAFNE and delayed DAFNE groups at six months. Values are means
(standard deviations) unless stated otherwise
Group
Glycated haemoglobin
(HbA1c, %)
Proportion of
participants
experiencing severe
hypoglycaemia in
previous six months*
(No (%))
Audit of diabetes›dependent quality of life (ADDQoL)
Weighted impact of
diabetes on “freedom to
eat as I wish”†
Average weighted
impact of diabetes on
quality of life† Present quality of life‡
Immediate DAFNE:
Baseline 9.4 (1.2) 15/68 (22) −4.8 (2.9) −2.0 (1.6) 1.0 (0.9)
Six months 8.4 (1.2) 12/67 (18) −1.8 (2.3) −1.6 (1.6) 1.3 (0.9)
Delayed DAFNE:
Baseline 9.3 (1.1) 8/72 (11) −4.0 (2.9) −1.9 (1.3) 1.1 (0.8)
Six months 9.4 (1.3) 11/72 (15) −4.0 (2.8) −1.9 (1.4) 1.0 (1.1)
Difference between groups at six months
Mean (95% CI) 1.0 (0.5 to 1.4) – 2.2 (1.3 to 3.1)§ 0.4 (−0.1 to 0.9)§ 0.3 (−0.1 to 0.6)§
Statistical values t=4.4, P<0.0001 ÷2=0.17, P=0.68 t=−5.4, P<0.0001 t=2.9, P<0.01 t=1.7, P=0.095
*Percent of participants; ÷2 test performed for differences between groups at six months.
†Scored from −9 (maximum negative impact) to +9 (maximum positive impact).
‡Scored from −3 (extremely bad) to +3 (excellent); 0=neither good nor bad, 1=good, 2=very good.
§Confidence interval should be interpreted with caution as variables were transformed before parametric analysis was performed but natural data are reported.
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Examples included “I now feel able to travel abroad
without worry about not eating or eating on time”
(change in average weighted impact score=0.28); “I
have found my whole lifestyle and outlook on life has
improved” (change=1.08); and “Because I now have
better control than ever before I will hopefully cut back
on any complications I may have incurred in the
future” (change=2.74). The difference in “present qual›
ity of life” did not reach significance at six months.
Twelve months after training (assessed only in
immediate DAFNE) HbA1c remained significantly
improved (fig 2) compared with baseline (mean differ›
ence 0.5%, 95% confidence interval 0.2 to − 0.9; t=3.5,
P=0.001). One quarter (16/67) of participants main›
tained a fall in HbA1c of > 1.5%, and four (6%) showed
a rise of > 1.5%. The number of participants
experiencing severe hypoglycaemia did not increase
significantly.
Improvements in the impact of diabetes on dietary
freedom were maintained between six and 12 months
(fig 3), with highly significant improvements from base›
line to 12 months (mean difference − 2.7, − 3.3 to
− 2.1; t=10.1, P < 0.0001). The impact of diabetes on
quality of life in general (average weighted impact
score) was further improved (mean difference from
baseline to 12 months − 0.7, − 1.1 to − 0.4; t=7.2,
P < 0.0001) (fig 3). “Present quality of life” also contin›
ued to improve and reached significance by one year
(mean difference baseline to 12 months − 0.5, − 0.8 to
− 0.2; t=3.6, P < 0.001) (fig 3).
Secondary outcomes
Table 2 shows the data for the secondary outcomes. We
found a significant improvement in psychological well›
being and satisfaction with treatment at six months and
a significant decrease in perceived frequency of hyper›
glycaemia. Twelve months after training psychological
wellbeing had continued to improve to a mean of 24.7
(mean difference from baseline to 12 months − 3.6,
− 5.0 to − 2.2; t= − 5.0, P < 0.0001). Treatment satisfac›
tion remained significantly higher, with a 12 month
mean of 31.0 (mean difference from baseline to 12
months − 7.5, − 9.1 to − 5.9; t=10.8, P < 0.0001).
Cardiovascular risk factors and perceived frequency of
hypoglycaemia did not change significantly in either
group across the trial. Mean blood pressure in the
immediate DAFNE group was 133 (SD 16)/79 (9.5)
mm Hg at baseline and 133 (14)/78 (10) mm Hg at 12
months.
The mean number of injections per day increased
in both groups after DAFNE training—from 3.6 at
baseline to 5.3 at 12 months (t=10.6, P < 0.001) in
immediate DAFNE and from 3.5 at baseline to 5.2 at
12 months (t=13.9, P < 0.001) in delayed DAFNE. Aver›
age insulin dose increased by a small but significant
amount in immediate DAFNE at 12 months compared
with baseline (from 0.71 to 0.74 U/kg; t= − 2.0,
P=0.017) but was unchanged in delayed DAFNE (from
0.71 to 0.70 U/kg; t=0.7, P=0.47).
Discussion
Our data show that a structured training course
(designed to maintain glucose control while enabling
dietary freedom) teaching self management skills to
patients with type 1 diabetes was effective over the
short term in a British healthcare setting. DAFNE
training significantly improved glycated haemoglobin,
with no significant increase in severe hypoglycaemia.
The training also produced sustained positive effects
on quality of life, satisfaction with treatment, and
psychological wellbeing, despite an increase in the
number of insulin injections and encouragement to
increase blood glucose monitoring. Despite increased
dietary freedom (as shown by responses to the
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Fig 2 Glycaemic control as measured by glycated haemoglobin
(HbA1c)
Table 2 Secondary outcomes: differences between immediate DAFNE and delayed DAFNE groups at six months. Values are means (SDs) unless stated
otherwise
Group
W›BQ12 Diabetes treatment satisfaction questionnaire (DTSQ) Cardiovascular risk factors
Total wellbeing* Total satisfaction*
Perceived frequency† of:
Weight (kg)
Total
cholesterol
(mmol/l)
HDL cholesterol
(mmol/l)
Triglycerides
(mmol/l)Hyperglycaemia Hypoglycaemia
Immediate DAFNE:
Baseline 20.94 (5.8) 22.88 (6.2) 3.57 (1.4) 2.04 (1.2) 80.5 (16.7) 5.2 (0.9) 1.5 (0.4) 1.5 (0.9)
6 months 24.34 (5.7) 31.58 (3.9) 2.90 (1.4) 2.16 (1.3) 81.5 (16.9) 5.1 (0.8) 1.6 (0.4) 1.4 (0.7)
Delayed DAFNE:
Baseline 21.09 (5.8) 23.21 (5.8) 3.60 (1.6) 2.12 (1.4) 77.4 (13.4) 4.9 (0.8) 1.5 (0.5) 1.5 (0.9)
6 months 21.37 (5.5) 22.82 (6.0) 4.03 (1.3) 2.40 (1.3) 77.3 (13.4) 5.0 (1.0) 1.5 (0.3) 1.5 (0.9)
Difference between groups at six months
Mean (95% CI) 2.98
(1.06 to 4.89)
8.75
(7.02 to 10.48)‡
−1.13
(−1.59 to −0.67)
−0.23
(−0.68 to 0.21)
4.18
(−0.90 to 9.27)
0.15
(−0.16 to 0.45)
0.09
(−0.01 to 0.22)
0.12
(−0.41 to 0.17)
Statistical values t=3.1, P<0.01 t=−10.3, P<0.0001 t=−4.88, P<0.0001 t=−1.0, P=0.31 t=1.6, P=0.11 t=0.95, P=0.34 t=1.46, P=0.14 t=0.83, P=0.41
HDL=high density lipoprotein; W›BQ12=12›item well›being questionnaire.
*Scored from 0 to 36; a higher score indicates greater wellbeing or satisfaction.
†Scored from 0 to 6; a higher score indicates greater perceived frequency of hyperglycaemia or hypoglycaemia.
‡Confidence interval should be interpreted with caution as variable was transformed before parametric analysis was performed but natural data are reported.
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“freedom to eat as I wish” item in the audit of diabetes›
dependent quality of life), we observed no deteriora›
tion in cardiovascular risk factors. These results are
encouraging and suggest that people with established
diabetes, when taught appropriate skills, will intensify
management of their diabetes and that this can be (and
perhaps needs to be) associated with improved quality
of life.
As with any randomised controlled trial, a crucial
question is how readily the observed effects might be
transferred to the wider population of adults with type
1 diabetes. The participants may have been atypical in
the impact of diabetes on their quality of life, their dis›
satisfaction with current treatment, and their willing›
ness to inject insulin five times a day. However, the fact
that a third of patients attending routine hospital clin›
ics expressed interest in participating after a single
unsolicited advertisement is encouraging. Other
studies have shown that current management of
diabetes in the United Kingdom leads to negative
effects on quality of life comparable to those seen in
our participants at baseline, indicating that many
patients with type 1 diabetes stand to benefit from a
more flexible approach with increased dietary free›
dom.4 5 The presentation of the course to patients as a
trial may have deterred some, but many patients who
are reluctant to participate in research might attend
training as part of standard treatment, especially once
our findings are known.
Many participants had a relatively long duration of
diabetes, with well established, albeit imperfect,
strategies for coping with the condition. Patients with a
shorter duration of diabetes might prove even more
receptive to a flexible, intensive approach. DAFNE
training, by facilitating a more flexible lifestyle, might
also encourage patients with tight glycaemic control
(who were excluded from the trial), particularly those
experiencing severe hypoglycaemia, to maintain tight
glycaemic targets with greater safety and less damage
to quality of life.
The fall in HbA1c at the six month analysis was
comparable to that reported in similar interventions.
The Dusseldorf group reported a lower HbA1c (by
1.5%) one year after training, compared with group
teaching of diabetes related information alone,11 and
similar improvements have been maintained for three
and six years.12 13 We did not see this in the immediate
DAFNE group at one year; HbA1c rose slightly from the
six month value, although it remained statistically and
clinically significantly lower than at baseline. The UK
participants had a longer duration of diabetes than
those in earlier studies and were discharged to a
healthcare system unfamiliar with this approach. We
avoided proactive follow up by DAFNE educators in
order to evaluate the effects of the course alone. We
might have expected some deterioration without
specific reinforcement or feedback of HbA1c.
As with any complex intervention, it is difficult to
know which aspects contributed to its effect. Control
participants received only usual care, and it is possible
that the benefits were merely the result of patients
spending five days intensively focusing on diabetes,
receiving attention from enthusiastic educators. How›
ever, the diabetes control and complications trial was
unable to show any improvements in quality of life,2
and evidence in type 2 diabetes suggests that improve›
ments in audit of diabetes›dependent quality of life
scores and HbA1c cannot be achieved by empower›
ment alone.14
Not everyone with type 1 diabetes will wish to
undertake intensive insulin treatment, even without
dietary restrictions; some will prefer a simpler regimen
with routine meal timing and fewer injections. Such
options will still be needed. Nevertheless, as the only
way of reducing microvascular disease currently is by
maintaining tight glycaemic control, we need better
ways of enabling patients to intensify their insulin
treatment. This study builds on earlier work and shows
that skills training and unrestricted food choices can be
applied successfully across different healthcare sys›
tems. The follow up of our patients was, however, rela›
tively short. We now need to establish whether similar
results can be achieved in routine care and devise ways
of sustaining improvement in glycaemic control.
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Fig 3 Reported impact of diabetes on “freedom to eat as I wish”
(top; n=123), average weighted impact of diabetes on quality of life
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Conclusion
We have shown, in a group of volunteers, that skills
training in insulin adjustment that provides patients
with the ability to fit diabetes into their lives rather than
their lives into diabetes improves quality of life and gly›
caemic control in the short term. The DAFNE
approach has the potential to reduce the incidence of
microvascular complications and thereby protect qual›
ity of life in the long term, as well as the short term, and
is worthy of further investigation.
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What is already known on this topic
Current treatment of type 1 diabetes fails to
engage many patients in intensive self
management and is associated with poor
glycaemic outcomes and impaired quality of life
An approach to intensive insulin treatment in
which participants match insulin dose to
unrestricted food choices has been developed in
Germany
This approach has been shown to lead to
sustained improvements in glycaemic control but
has not been widely adopted elsewhere
What this study adds
Training in flexible, intensive insulin treatment can
improve glycaemic control in the United Kingdom
This approach also leads to significant
improvements in treatment satisfaction,
psychological wellbeing, and quality of life
measures
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